<DOC>
	<DOCNO>NCT00039468</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth glioblastoma multiforme stop blood flow tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining thalidomide irinotecan may kill tumor cell remain radiation therapy . PURPOSE : Phase II trial study effectiveness combine thalidomide irinotecan treating patient glioblastoma multiforme treat radiation therapy .</brief_summary>
	<brief_title>Thalidomide Irinotecan Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient glioblastoma multiforme treat thalidomide irinotecan radiotherapy . - Determine preliminary efficacy regimen patient . - Determine disease-free survival overall survival patient treat regimen . - Determine toxicity regimen patient . - Assess quality life patient treat regimen . OUTLINE : Beginning 2-4 week completion radiotherapy , patient receive irinotecan IV 90 minute day 1 . Patients also receive oral thalidomide daily . Treatment repeat every 21 day least 3 course absence disease progression unacceptable toxicity . Quality life assess baseline , 1 week first course , prior subsequent course , course 6 . Patients follow 5 year . PROJECTED ACCRUAL : A total 9-24 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme ( GBM ) Recurrent disease allow Evaluable disease contrastenhanced MRI Prior external beam radiotherapy require PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 5 time ULN Renal : Creatinine great 1.5 time ULN OR Creatinine clearance least 60 mL/min Cardiovascular : No significant cardiac disease No uncontrolled high blood pressure No unstable angina No congestive heart failure No myocardial infarction within past 3 month No serious cardiac arrhythmia Gastrointestinal : Able take oral medication No gastrointestinal abnormalities No requirement IV alimentation No active peptic ulcer disease Other : No active infection No serious uncontrolled medical disorder No dementia significantly alter mental status would preclude study No known hypersensitivity irinotecan thalidomide Not pregnant nursing Negative pregnancy test Fertile patient must use 2 form effective contraception , include 1 highly effective method , least 1 month , , 1 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior thalidomide Chemotherapy : No prior irinotecan At least 4 week since prior chemotherapy ( demonstrated evidence disease progression relapse ) Endocrine therapy : Concurrent corticosteroid allow stable decrease dose least 1 week prior study No concurrent hormonal therapy GBM Radiotherapy : See Disease Characteristics No concurrent radiotherapy GBM Surgery : No prior surgical procedure affect absorption Other : No concurrent anticancer investigational agent GBM No concurrent cytochrome P450 inhibitor , include follow : Nefazodone Fluvoxamine Fluoxetine Sertraline Paroxetine Venlafaxine Ketoconazole Itraconazole Fluconazole Cimetadine Clarithromycin Diltiazem Erythromycin Protease inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>